Clinical effect of recombinant human interferon α1b adjuvant therapy in infectious mononucleosis: a prospective randomized controlled trial.
- Author:
Sha-Sha DAI
1
;
Kai ZHOU
Author Information
1. Department of Infectious Diseases, Children's Hospital Affiliated to Nanjing Medical University, Nanjing 210000, China. kx06m1@163.com.
- Publication Type:Journal Article
- MeSH:
Antigens, CD19;
Hepatomegaly;
Humans;
Infectious Mononucleosis;
Prospective Studies;
Splenomegaly
- From:
Chinese Journal of Contemporary Pediatrics
2020;22(9):953-957
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study the clinical effect of recombinant human interferon α1b assisting acyclovir on immune function, inflammatory factors, and myocardial zymogram in children with infectious mononucleosis (IM).
METHODS:A total of 182 children with IM who were admitted to the hospital from January to December, 2018, were divided into an observation group with 91 children and a control group with 91 children using a random number table. The children in the control group were treated with intravenous drip of acyclovir, and those in the observation group were treated with inhalation of recombinant human interferon α1b in addition to the treatment in the control group. The two groups were compared in terms of clinical symptoms, immune function, inflammatory response, myocardial zymogram, and adverse reactions.
RESULTS:Compared with the control group, the observation group had significantly shorter time to body temperature recovery and disappearance of isthmopyra, cervical lymph node enlargement, hepatomegaly, and splenomegaly (P<0.05). After treatment, both groups had significant increases in CD4, CD4/CD8, and CD19, and the observation group had significantly higher levels of these markers than the control group (P<0.05). After treatment, both groups had significant reductions in the levels of CD8+, tumor necrosis factor-α, interlukin-6, creatine kinase, and creatine kinase-MB, and the treatment group had significantly lower levels of these markers than the control group (P<0.05). There was no significant difference in the incidence rate of adverse reactions between the two groups after treatment (P>0.05).
CONCLUSIONS:For children with IM, recombinant human interferon α1b assisting acyclovir can effectively improve immune function, inhibit inflammatory reaction, reduce myocardial injury, and thus alleviate clinical symptoms.
